Equities

Glycorex Transplantation AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Glycorex Transplantation AB (publ)

Actions
  • Price (SEK)1.54
  • Today's Change0.055 / 3.70%
  • Shares traded4.82k
  • 1 Year change-40.08%
  • Beta0.9496
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Glycorex Transplantation AB (publ) is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. The Company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants.

  • Revenue in SEK (TTM)39.94m
  • Net income in SEK-7.06m
  • Incorporated1995
  • Employees20.00
  • Location
    Glycorex Transplantation AB (publ)Scheelevagen 27LUND 223 63SwedenSWE
  • Phone+46 462865230
  • Fax+46 462865239
  • Websitehttps://glycorex.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chosa Oncology AB717.00k-6.01m65.48m----4.06--91.33-0.0766-0.07660.00960.20440.0382--0.8639---32.00-55.65-35.30-67.69643.24---837.66-792.50---49.050.00---39.73-62.5659.93------
Lifecare ASA1.71m-116.19m72.15m28.00------42.11-2.48-2.480.0379-0.110.0168--0.158255,272.73-115.30-52.64-194.19-61.98-----6,864.75-277.39----1.17---26.1036.13-103.52------
Opsy Holding AB4.13m-18.69m76.18m7.00--49.33--18.45-20.83-20.830.63210.12160.294--7.632,064,500.00-133.11-117.68-201.35-142.11154.30---452.72-----216.840.463-------43.22------
Spago Nanomedical AB (publ)437.00k-26.55m79.39m7.00--2.58--181.67-0.0513-0.05130.00080.04650.0115--4.3962,428.57-69.64-30.44-81.41-32.48-----6,076.43-3,410.33---------77.135.0218.32------
IDL Diagnostics AB (publ)52.19m-39.31m85.00m22.00--0.5681--1.63-0.1706-0.17060.22660.64950.32636.595.262,372,364.00-24.58-29.04-26.98-31.1421.531.70-75.32-157.603.29--0.0843--33.45164.6228.41--18.85--
Alligator Bioscience AB42.25m-77.72m95.14m13.00------2.25-2.16-2.160.6369-0.05920.5013--9.35938,822.30-92.22-97.96---155.50-----183.96-569.04----1.33---0.585167.685.91------
Coegin Pharma AB0.00-20.64m99.01m3.00--8.50-----0.7859-0.78590.000.46810.00----0.00-85.07-133.34-91.51-179.59------------0.00------15.00------
Annexin Pharmaceuticals AB (publ)0.00-36.89m100.95m4.00--4.05-----5.98-5.980.003.530.00----0.00-150.00-137.53-190.93-169.50------------0.00------26.58------
Biosergen AB0.00-40.82m102.38m1.00---------17.68-17.680.00---------------------------------------112.64------
Active Biotech AB publ0.00-38.50m103.60m5.00--13.54-----0.0737-0.07370.000.00290.00----0.00-241.37-94.38-927.66-120.44-------3,355.24----0.0816------13.98------
Biovica International AB9.86m-76.47m110.39m24.00--0.9455--11.19-0.6375-0.63750.06840.42410.079912.714.46365,333.30-61.92-58.22-70.41-66.49-171.53-462.09-775.22-1,804.168.11--0.0239--18.2338.8329.80---47.26--
Glycorex Transplantation AB (publ)39.94m-7.06m112.25m20.00--3.1547.702.81-0.0917-0.09170.51740.47190.74421.455.201,997,000.00-13.15-15.79-17.51-18.6681.6887.06-17.67-44.851.56-15.830.1599--17.35-0.529663.97------
Exact Therapeutics AS0.00-67.82m115.88m12.00--1.82-----1.40-1.400.001.070.00----0.00-108.82-43.50-168.39-50.76-----------20.180.0052-------8.27--1.47--
Abera Bioscience AB0.00-10.45m116.44m5.00--6.04-----0.5692-0.56920.001.040.00-------49.58-63.36-74.82-81.05---------------------850.27------
Alzinova AB205.00k-26.88m122.02m5.00--0.5965--595.20-0.2846-0.28460.00221.230.0015--0.325441,000.00-19.42-12.21-20.69-12.85-5,834.15---13,114.15-21,390.81---1,794.800.0062---88.89---24.71--19.48--
SoftOx Solutions AS12.76m-2.82m136.35m5.00--1.34180.2310.68-0.001-0.0010.00650.04450.123--30.132,717,798.00-2.72-50.91-3.22-67.07-----22.07-644.921.16-3.920.1212--13.3814.06-8.86------
Data as of Feb 16 2026. Currency figures normalised to Glycorex Transplantation AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

1.97%Per cent of shares held by top holders
HolderShares% Held
Skandia Fonder ABas of 30 Dec 20241.49m1.97%
Evli Fund Management Co. Ltd.as of 30 Aug 20243.00k0.00%
Data from 28 Nov 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.